Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Tempest Therapeutics, Inc. (OVAS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/11/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update Brisbane, CA, August 10, 2023 – Tempest Therapeutics, Inc. , a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended June 30, 2023 and provided a corporate update. “2023 continues to be a productive and potentially transformative year for Tempest,” said Stephen Brady, chief executive officer of Tempest. “In the second quarter, we presented data from our second clinical program, TPST-1495, the company’s novel dual EP2/EP4 antagonist designed to selectively modulate the prostaglandin pathway, both at ASCO and in a paper published in Cancer Research Communicati..." |
|
| 06/16/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Tempest Reports First Quarter 2023 Financial Results and Provides Business Update Brisbane, CA, May 10, 2023 – Tempest Therapeutics, Inc. , a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended March 31, 2023 and provided a corporate update. “The first few months of 2023 set the pace for what we believe will be a transformative year for Tempest,” said Stephen Brady, chief executive officer of Tempest. “Recently, we announced exciting early data showing that TPST-1120, the company’s PPAR⍺ antagonist, combined with standard of care in first-line HCC patients demonstrated clinically meaningful improvement in multiple categories, incl..." |
|
| 04/28/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
8-K
| Other Events Interactive Data |
| 03/22/2023 |
8-K
| Quarterly results |
| 12/29/2022 |
8-K
| Quarterly results |
| 11/08/2022 |
8-K
| Quarterly results |
| 09/23/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/15/2022 |
8-K
| Quarterly results |
| 06/21/2022 |
8-K
| Quarterly results |
| 06/09/2022 |
8-K
| Quarterly results |
| 05/26/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/13/2022 |
8-K
| Quarterly results |
| 05/02/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Form of Pre-Funded Warrant",
"Securities Purchase Agreement, dated April 26, 22, by and among Tempest Therapeutics, Inc. and the persons party thereto",
"Registration Rights Agreement, dated April 26, 22, by and among Tempest Therapeutics, Inc. and the persons party thereto",
"Tempest Announces Private Placement Financing of $15 Million",
"Tempest Announces Oral and Poster Presentations at the Upcoming 2022 ASCO Annual Meeting • Oral presentation for TPST-1120 completed Phase 1 trial results • Poster presentation for TPST-1495 trial in progress South San Francisco, CA, April 27, 2022 - Tempest Therapeutics, Inc. , a clinical-stage oncology company developing therapeutics that combine both targeted and immune-mediated mechanisms, today announced that two abstracts were accepted for presentation at the 2022 American Society of Clinical Oncology Annual Meeting taking place June 3-7, 2022 at the McCormick Place Convention Center in Chicago, IL. The results of the Phase 1 monotherapy and Phase 1 combination therapy studies with TPST-1120, a potential first-in-class PPARα antagonist, received an invitation for an oral present..." |
|
| 03/29/2022 |
8-K
| Quarterly results |
| 12/23/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/10/2021 |
8-K
| Quarterly results |
| 09/24/2021 |
8-K
| Quarterly results |
| 08/12/2021 |
8-K
| Quarterly results |
| 07/23/2021 |
8-K
| Other Events, Financial Statements and Exhibits |
| 07/16/2021 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report : July 16, 2021 TEMPEST THERAPEUTICS, INC. Delaware 001-35890 45-1472564 7000 Shoreline Court, Suite 275 South San Francisco, CA 94080 Registrant's telephone number, including area code: 798-8589 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐...",
"Consent of Deloitte & Touche LLP for Tempest",
"Company Business Section",
"Company Risk Factors",
"Management's Discussion and Analysis of Tempest for the Quarterly Period ended March 31, 2021",
"Audited Financial Statements of Tempest as of December 31, 2020 and 2019",
"Unaudited Pro Forma Condensed Combined Financial Information" |
|
| 07/12/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/07/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Form of Indemnification Agreement",
"Form of Indemnification Agreement",
"Employment Agreement, by and between the Company and Stephen Brady",
"Employment Agreement, by and between the Company and Thomas Dubensky, Ph.D",
"Employment Agreement, by and between the Company and Samuel Whiting, M.D., Ph.D" |
|
| 06/28/2021 |
8-K
| Appointed a new director|
Docs:
|
"Certificate of Amendment to the Restated Certificate of Incorporation of the Company",
"Certificate of Amendment to the Restated Certificate of Incorporation of the Company",
"Tempest Closes Merger with Millendo and Completes PIPE Financing South San Francisco, CA, June 28, 2021 -Tempest Therapeutics, Inc. , a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, announced today the closing of its merger with Millendo Therapeutics, Inc. . Tempest's stock will commence trading on June 28, 2021 on the Nasdaq Global Select Market under the trading symbol “TPST.” In support of the merger, Tempest secured investments from a premier syndicate of healthcare investors composed of Versant Ventures, Rock Springs Capital, F-Prime Capital, Monashee Investment Management, Quan Capital, Lyfe Capital, Maven Investment Partners US, Lilly Asia Ventures and Eight Roads Ventures for a $30 milli..." |
|
| 06/11/2021 |
8-K
| Quarterly results |
| 03/29/2021 |
8-K
| Quarterly results |
| 01/28/2021 |
8-K
| Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm... |
| 01/05/2021 |
8-K
| Quarterly results |
| 09/24/2020 |
8-K
| Quarterly results |
| 06/23/2020 |
8-K
| Quarterly results |
| 04/06/2020 |
8-K
| Cost Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits |
| 03/04/2020 |
8-K
| Quarterly results |
|
|
|